Jersey City, NJ, United States of America

Nihar Kinarivala

This inventor holds 1 USPTO granted patent. Top assignee: Texas Tech University System. Active years: 2022.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nihar Kinarivala: Innovator in Neuroprotective Compounds

Introduction

Nihar Kinarivala is a notable inventor based in Jersey City, NJ (US). He has made significant contributions to the field of neuroprotective compounds, particularly through his innovative research and patent work. His dedication to advancing medical science is evident in his latest patent, which addresses neurodegenerative disorders.

Latest Patents

Kinarivala holds a patent for "Functionalized pyridine carbamates with enhanced neuroprotective activity." This invention includes compositions and methods for treating subjects afflicted with neurodegenerative disorders. The patent outlines a process for determining the need for treatment and administering an effective amount of a compound comprising a flupirtine derivative.

Career Highlights

Kinarivala is affiliated with the Texas Tech University System, where he continues to engage in research and development. His work focuses on creating innovative solutions for complex medical challenges, particularly in the realm of neuroprotection.

Collaborations

Throughout his career, Kinarivala has collaborated with esteemed colleagues such as Paul Trippier and Rose-Mary Boustany. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Nihar Kinarivala's contributions to the field of neuroprotective compounds exemplify his commitment to improving health outcomes for individuals with neurodegenerative disorders. His innovative work and collaborations position him as a key figure in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…